Mouse Anti-Albendazole monoclonal antibody, clone ABZ2

Neglected tropical diseases afflict more than 1 billion of the world's poorest people. Pharmaceutical donations of preventive chemotherapy for neglected tropical diseases enable the largest en masse treatment campaigns globally with respect to the number of people targeted for treatment. However, the blanket distribution of medicines at no cost to individuals in need of treatment does not guarantee that those individuals are treated. In this Personal View, we aim to examine the next steps that need to be taken towards ensuring equitable treatment access, including health system integration and the role of endemic countries in ensuring medicines are delivered to patients. We argue that the expansion of medicine donation programmes and the development of new medicines are not the primary solutions to sustaining and expanding the growth of neglected tropical disease programmes. Treatment is often not verified by a medical professional, independent surveyor, or national programme officer. Additionally, access to medicines might not be equitable across at-risk populations, and treatment targets for disease control remain largely unmet within many endemic countries. To enable equitable access and efficient use of existing medicines, research is needed now on how best to integrate the treatment of neglected tropical diseases into local health systems. A comprehensive approach should be used, which combines mass drug administration with on-demand access to treatment. Increased commitment by endemic countries, when possible, around the ownership of treatment campaigns is essential to improve access to medicines for neglected tropical diseases.

Background The current World Health Organization (WHO) target for the three major soil-transmitted helminth (STH) infections is to reduce prevalence of moderate-to-heavy infections to below 1% by 2020. In terms of monitoring and evaluation (M&E), the current WHO guidelines for control of STHs recommend evaluation of infection levels in school-age children (SAC) after five to six years of preventive chemotherapy (PC), using the standard Kato-Katz faecal smear. Here, we assess the predictive performance of various sampling designs for the evaluation of the morbidity target. Methodology/Principal findings Using two mathematical models for STH transmission and control, we simulate how the number of villages and SAC sampled affect the ability of survey results in sentinel villages to predict the achievement of the morbidity target in PC implementation units (e.g. district). As PC is stopped when the prevalence of infection in SAC in sentinel villages is less than 1%, we estimate the positive predictive value (PPV) of this indicator for meeting the morbidity target in the whole district. The PPV varies by species and PC strategy, and it is generally higher in areas with lower pre-control prevalence. Sampling a fixed number of SAC spread out over 10 instead of 5 sentinel villages may increase the PPV by up to 20 percentage points. If every SAC in a village is tested, a higher number of villages may increase the PPV by up to 80 percentage points. Increasing the proportion of SAC tested per village does not result in a relevant increase of PPV. Conclusions/Significance Although the WHO guidelines provide a combined strategy to control the three STH species, the efficacy of PC strategies clearly differs by species. There is added value in considering more villages within implementation units for M&E of morbidity targets, the extent varying by STH species. A better understanding of pre- and post-control local STH prevalence levels is essential for an adequate M&E strategy including the definition of morbidity targets at the appropriate geographical scale. Author summary Soil-transmitted helminths (STHs) affect approximately 1.5 billion people worldwide. The World Health Organization target for STHs is to achieve <1% prevalence of moderate-to-heavy infection among school-age children (SAC) through preventive chemotherapy (PC) with albendazole or mebendazole. For monitoring and evaluation (M&E) of STH infections, it is recommended to assess the infection levels in SAC after five to six years of treatment and to stop PC if the prevalence of infection is <1%. In this study, we use two mathematical models to assess the predictive performance of different sampling designs for the evaluation of the morbidity target. We find that the efficacy of PC strategies differs significantly by species and pre-control infection levels. Achieving 1% prevalence of infection in sentinel villages may still imply a prevalence of moderate-to-heavy infections >1% in the entire PC implementation unit. Evaluating the prevalence of any infection over a higher number of sentinel villages improves the accuracy in assessing the morbidity target at the implementation unit level, even when a lower proportion of SAC per village is tested. A better understanding of pre- and post-control local STH prevalence levels through large scale data collection is essential for the definition of an adequate M&E strategy for STH control.